Tags

Type your tag names separated by a space and hit enter

[Protective effects of recombinant SCR15-18 domain of human soluble complement receptor type 1 on myocardial ischemia and reperfusion injury].
Zhonghua Xin Xue Guan Bing Za Zhi. 2007 Nov; 35(11):1037-40.ZX

Abstract

OBJECTIVE

To investigate the protective effects of recombinant SCR15-18 domain of human soluble complement receptor type 1 (sCR1-SCR-15-18) in rats underwent myocardial ischemia and reperfusion (I/R).

METHODS

Sprague-Dawley rats were randomly divided into three groups (n = 12 each group): sham (SO); 30 min ischemia/3h reperfusion (I/R) and I/R plus sCR1-SCR15-18 (15 mg/kg before I/R, sCR1). Serum LDH, CK and cardiac myeloperoxidase (MPO) activity were measured. Infarct size, myocardial histopathological changes and myocardial C3c were also compared among groups.

RESULTS

Infarct size [(16.1 +/- 3.3)% vs. (22.9 +/- 3.0)%, infarct zone/left ventricular mass, P < 0. 05] and CK [(2532.5 +/- 597.1) U/L vs. (3400.9 +/- 534.9) U/L, P < 0. 05] and LDH [(5436.2 +/- 611.3) U/L vs. (6572.0 +/- 476.3) U/L, P < 0. 05] as well as MPO activity in infarct zone [(0.81 +/- 0.14) U/g vs. (1.12 +/- 0.13) U/g, P < 0.05] were significantly decreased post sCR1 compared to I/R group. sCR1 also significantly attenuated histological myocardial injury and reduced the deposition of C3c in infarct zone.

CONCLUSION

sCR1-SCR15-18 protein exerts cardioprotective effects in this rat I/R model.

Authors+Show Affiliations

Department of Microbiology, College of Medicine, Third Military Medical University, Chongqing 400038, China.No affiliation info availableNo affiliation info available

Pub Type(s)

English Abstract
Journal Article
Research Support, Non-U.S. Gov't

Language

chi

PubMed ID

18269827

Citation

Tan, Bing, et al. "[Protective Effects of Recombinant SCR15-18 Domain of Human Soluble Complement Receptor Type 1 On Myocardial Ischemia and Reperfusion Injury]." Zhonghua Xin Xue Guan Bing Za Zhi, vol. 35, no. 11, 2007, pp. 1037-40.
Tan B, Lan YJ, Zhang DC. [Protective effects of recombinant SCR15-18 domain of human soluble complement receptor type 1 on myocardial ischemia and reperfusion injury]. Zhonghua Xin Xue Guan Bing Za Zhi. 2007;35(11):1037-40.
Tan, B., Lan, Y. J., & Zhang, D. C. (2007). [Protective effects of recombinant SCR15-18 domain of human soluble complement receptor type 1 on myocardial ischemia and reperfusion injury]. Zhonghua Xin Xue Guan Bing Za Zhi, 35(11), 1037-40.
Tan B, Lan YJ, Zhang DC. [Protective Effects of Recombinant SCR15-18 Domain of Human Soluble Complement Receptor Type 1 On Myocardial Ischemia and Reperfusion Injury]. Zhonghua Xin Xue Guan Bing Za Zhi. 2007;35(11):1037-40. PubMed PMID: 18269827.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Protective effects of recombinant SCR15-18 domain of human soluble complement receptor type 1 on myocardial ischemia and reperfusion injury]. AU - Tan,Bing, AU - Lan,Yang-Jun, AU - Zhang,De-Chun, PY - 2008/2/14/pubmed PY - 2009/8/12/medline PY - 2008/2/14/entrez SP - 1037 EP - 40 JF - Zhonghua xin xue guan bing za zhi JO - Zhonghua Xin Xue Guan Bing Za Zhi VL - 35 IS - 11 N2 - OBJECTIVE: To investigate the protective effects of recombinant SCR15-18 domain of human soluble complement receptor type 1 (sCR1-SCR-15-18) in rats underwent myocardial ischemia and reperfusion (I/R). METHODS: Sprague-Dawley rats were randomly divided into three groups (n = 12 each group): sham (SO); 30 min ischemia/3h reperfusion (I/R) and I/R plus sCR1-SCR15-18 (15 mg/kg before I/R, sCR1). Serum LDH, CK and cardiac myeloperoxidase (MPO) activity were measured. Infarct size, myocardial histopathological changes and myocardial C3c were also compared among groups. RESULTS: Infarct size [(16.1 +/- 3.3)% vs. (22.9 +/- 3.0)%, infarct zone/left ventricular mass, P < 0. 05] and CK [(2532.5 +/- 597.1) U/L vs. (3400.9 +/- 534.9) U/L, P < 0. 05] and LDH [(5436.2 +/- 611.3) U/L vs. (6572.0 +/- 476.3) U/L, P < 0. 05] as well as MPO activity in infarct zone [(0.81 +/- 0.14) U/g vs. (1.12 +/- 0.13) U/g, P < 0.05] were significantly decreased post sCR1 compared to I/R group. sCR1 also significantly attenuated histological myocardial injury and reduced the deposition of C3c in infarct zone. CONCLUSION: sCR1-SCR15-18 protein exerts cardioprotective effects in this rat I/R model. SN - 0253-3758 UR - https://www.unboundmedicine.com/medline/citation/18269827/[Protective_effects_of_recombinant_SCR15_18_domain_of_human_soluble_complement_receptor_type_1_on_myocardial_ischemia_and_reperfusion_injury]_ L2 - http://journal.yiigle.com/LinkIn.do?linkin_type=pubmed&amp;issn=0253-3758&amp;year=2007&amp;vol=35&amp;issue=11&amp;fpage=1037 DB - PRIME DP - Unbound Medicine ER -